Table 3.

Individual patient regression analysis of P/C ratios over timea

PatientInitial P/C RatiosbIntercept of P/C Ratio RegressioncSlope of P/C Ratios RegressionFollow-Up: Months on Agalsidase-βNo. of Complete Evaluations
CKD stages 1 and 2
    30.170.09−0.00324.93
    80.300.160.08934.89
    40.460.28−0.01924.77
    50.410.350.10634.98
    mean ± SD (median)0.34 ± 0.13 (0.36)0.22 ± 0.12 (0.22)d0.043 ± 0.063 (0.043)29.8 ± 5.8 (29.8)6.8 ± 2.6 (7.5)
CKD stages 3 and 4
    70.330.060.01630.39
    90.580.130.00542.214
    61.910.160.12643.029
    106.291.060.03837.121
    122.140.240.31910.813
    130.230.140.27521.67
    mean ± SD (median)1.91 ± 2.29 (1.24)0.30 ± 0.38 (0.15)e0.130 ± 0.137 (0.082)28.1 ± 14.7 (29.4)15.5 ± 8.2 (13.5)
  • a CKD, chronic kidney disease.

  • b Value obtained before ACEI/ARB therapy was initiated.

  • c Zero time assigned to the point at which ERT was initiated.

  • d P = 0.0161, two-tailed t test, comparing fourth-root transformation of regression intercept to initial P/C ratio.

  • e P = 0.0054, two-tailed t test, comparing fourth-root transformation of regression intercept to initial P/C ratio.